The estimated Net Worth of Howard B Rosen is at least $154 ezer dollars as of 19 August 2019. Mr. Rosen owns over 4,824 units of Kala Bio stock worth over $29,040 and over the last 14 years he sold KALA stock worth over $0. In addition, he makes $124,972 as Independent Director at Kala Bio.
Howard has made over 3 trades of the Kala Bio stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 4,824 units of KALA stock worth $2,894 on 19 August 2019.
The largest trade he's ever made was buying 10,206 units of Kala Bio stock on 13 May 2016 worth over $33,272. On average, Howard trades about 742 units every 44 days since 2011. As of 19 August 2019 he still owns at least 4,824 units of Kala Bio stock.
You can see the complete history of Mr. Rosen stock trades at the bottom of the page.
Howard B. Rosen serves as Independent Director of the Company. He has served as a member of our board of directors since January 2014. Since 2008, Mr. Rosen has served as a consultant to several companies in the biotechnology industry. He has also served as a lecturer at Stanford University in Chemical Engineering since 2009 and in Management since 2011. Mr. Rosen served as Chief Executive Officer of AcelRx Pharmaceuticals, Inc., or AcelRx, a public specialty pharmaceutical company developing products for pain relief, from April 2016 to March 2017, and Interim Chief Executive Officer from April 2015 to March 2016. Mr. Rosen also served as Interim President and Chief Executive Officer of Pearl Therapeutics, Inc. from June 2010 to March 2011. From 2004 to 2008, Mr. Rosen was Vice President of Commercial Strategy at Gilead Sciences, Inc., a biopharmaceutical company. From 2003 until 2004, Mr. Rosen was President of ALZA Corporation, a pharmaceutical and medical systems company that merged in 2001 with Johnson & Johnson, a global healthcare company. Prior to that, from 1994 until 2003, Mr. Rosen held various positions at ALZA Corporation. Mr. Rosen is a member of the board of directors of AcelRx, a public pharmaceutical company, and also served on the board of directors of Alcobra, Ltd., a public pharmaceutical company, until November 2017. Mr. Rosen is also currently a member of the board of directors of private companies, including Hammerton, Inc., Metera Pharmaceuticals, Inc. and Entrega, Inc., and was a member of the board of directors of PaxVax, Inc. from 2007 to 2015. Mr. Rosen holds a B.S. in Chemical Engineering from Stanford University, an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and an M.B.A. from the Stanford Graduate School of Business.
As the Independent Director of Kala Bio, the total compensation of Howard Rosen at Kala Bio is $124,972. There are 12 executives at Kala Bio getting paid more, with Mark Iwicki having the highest compensation of $2,556,170.
Howard Rosen is 62, he's been the Independent Director of Kala Bio since 2015. There are 2 older and 15 younger executives at Kala Bio. The oldest executive at Kala Bio Inc. is Dr. Kim Brazzell Ph.D., 68, who is the Head of R&D and Chief Medical Officer.
Howard's mailing address filed with the SEC is C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476.
Over the last 7 years, insiders at Kala Bio have traded over $2,579,128 worth of Kala Bio stock and bought 23,705,318 units worth $209,975,371 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... és Rajeev M. Shah. On average, Kala Bio executives and independent directors trade stock every 31 days with the average trade being worth of $2,090,132. The most recent stock trade was executed by Todd Bazemore on 26 June 2024, trading 4,653 units of KALA stock currently worth $22,102.
kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.
Kala Bio executives and other stock owners filed with the SEC include: